A Community Cornerstone
Janssen Therapeutics, Division of Janssen Products, LP
We’ve built
the framework
for a strong
alliance
We know that treatment
advancements can help
with individual success, and
individual success helps build
a strong foundation for the
HIV community.
At Janssen
Therapeutics,
we are dedicated
to moving
medicine forward
to enable life’s
moments
and milestones.
Janssen Therapeutics,
Division of Janssen Products, LP,
is one of the Janssen Pharmaceutical
Companies of Johnson & Johnson.
NHA
We are strong supporters
of the National HIV/AIDS
Strategy (NHAS), and
we demonstrate our
commitment to the HIV
community by aligning to
its 3 primary goals:
È
Reducing the number of people
who become infected with HIV
Increasing access to care and
improving health outcomes
for people living with HIV
È
We strive to make these goals
a primary focus in everything
we do, from the educational
materials that spread awareness
to the national programs
that provide critical support
and access to much-needed
antiretroviral (ARV) therapies.
Ç
Reducing HIV-related
health disparities
We put people living with HIV
first. Since 2006, Janssen has
introduced more novel HIV
medicines than any other
company, and entered into intercompany collaborations to develop
new combination medications.
That’s why our care extends far
beyond the company walls, right
into the heart of the community.
The
foundation for
personal
success
From understanding HIV
basics to learning how to gain
better access to medications,
we show our care by providing
accessible information.
There’s a lot of
information that
people living with HIV
should understand
about HIV and their
ARV treatments.
Educational
materials,
resources,
support, and
access
Providing educational materials
for people living with HIV
Digital Education
Interactive modules and discussion guides,
product-labeling information, videos about HIV
basics, patient testimonials, and HIV-dedicated
social media platforms
HIV
Office Materials
There are many different types of medicines to treat HIV (Human Immunodeficiency Virus). These medicines
are called antiretrovirals and they are grouped into classes.
medicines
Please be aware that HIV medicines, including EDURANT®, INTELENCE®, and PREZISTA®, do not cure HIV
infection, do not reduce the risk of transmission of HIV to others, and should always be taken in combination
with other HIV medicines as prescribed by your healthcare professional.†
*
• Follow your healthcare professional’s directions regarding the use of these medicines
• Discuss any questions you have about your treatment, including side effects and
health status, with your healthcare professional
• Products are not shown at actual size
PROTEASE INHIBITORS PIs
www.PREZISTA.com
PREZISTA®
darunavir
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS NNRTIs/non-nukes
www.EDURANT.com
EDURANT®
800 mg
rilpivirine
600 mg
Brochures covering HIV-related
health issues, an ARV pill chart, and
accompanying tearpad
25 mg
Aptivus
®
tipranavir
INTELENCE®
etravirine
250 mg
www.INTELENCE-info.com
100 mg
Crixivan®
indinavir sulfate
Rescriptor®
delavirdine mesylate
400 mg
200 mg
200 mg
Invirase®
saquinavir mesylate
Sustiva®
200 mg
efavirenz
500 mg
600 mg
Kaletra®
lopinavir/ritonavir
Viramune®/Viramune® XR™
nevirapine
200/50 mg
200 mg
Lexiva®
fosamprenavir calcium
400 mg
NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS NtRTIs/nukes
700 mg
Norvir®
Soft gel
(Refrigeration
recommended)
Tablet
(Room
temperature)
ritonavir
100 mg
Combivir®
lamivudine/
zidovudine
150/300 mg
100 mg
Emtriva®
Reyataz®
emtricitabine
atazanavir sulfate
150 mg
200 mg
250 mg
625 mg
200 mg
300 mg
Epivir®
Viracept®
lamivudine
nelfinavir mesylate
150 mg
Epzicom®
NtRTI/NNRTI MULTICLASS SINGLETABLET REGIMENS
abacavir sulfate/
lamivudine
300 mg
600/300 mg
Atripla®
efavirenz/emtricitabine/
tenofovir disoproxil fumarate‡
Retrovir®
zidovudine
600/200/300 mg
300 mg
Complera™
emtricitabine/rilpivirine/
tenofovir disoproxil fumarate‡
Trizivir®
abacavir sulfate/lamivudine/
zidovudine
200/25/300 mg
300/150/300 mg
INTEGRASE INHIBITORS
Truvada®
emtricitabine/tenofovir
disoproxil fumarate‡
Isentress®
raltegravir
200/300 mg
400 mg
Videx® EC
didanosine
ENTRY INHIBITORS
250 mg
Fuzeon®
400 mg
Viread®
enfuvirtide
tenofovir disoproxil
fumarate‡
90 mg (1 mL)
300 mg
Selzentry®
Zerit
maraviroc
®
stavudine
150 mg
300 mg
Community Speaker Programs
30 mg
*Indications, safety, and efficacy of these products may vary. Please refer to the full Prescribing Information or Patient Information
of each medication for more details.
†
This chart does not include all HIV treatment formulations, treatment options, or dosing or safety considerations for the use
of antiretroviral agents.
‡
Nucleotide reverse transcriptase inhibitor.
The brands listed are the registered trademarks of their respective owners. EDURANT® and INTELENCE® are registered trademarks of Tibotec
Pharmaceuticals. PREZISTA® is a registered trademark of Janssen Pharmaceuticals. Information provided is current as of May 2012.
Please see next page for Indication and Important Safety Information for EDURANT®,
INTELENCE®, and PREZISTA®.
Ziagen®
abacavir sulfate
40 mg
300 mg
Janssen Therapeutics, Division of Janssen Products, LP
Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, New Jersey 08560
© Janssen Therapeutics, Division of Janssen Products, LP 2012
05/12
28JT12021
Live promotional speaker
presentations
Therapy Initiation Kits
Helpful information to assist with
initiating therapy
Staying on Treatment
An assortment of programs to assist people
living with HIV in sticking with treatment,
including a mobile health management app
Providing support and access to
our medications
Patient Savings Program
Financial assistance and easy access to
medications and information
Ask your Janssen representative about the many
materials that are also available in Spanish.
Supporting
the HIV community
at large
The foundation for personal success
There’s a lot of information people living with HIV should
understand about HIV and their ARV treatments. From understanding
HIV basics to learning how to gain better access to medications, we
show our care by providing accessible information.
Providing educational materials
for people living with HIV
Educational Modules
Presentations, interactive programs, and
videos that cover basic HIV disease state
topics and are delivered to people living
with HIV by the Community Liaison team.
Brochure Series
Customizable educational brochures
on a variety of topics for people living
with HIV.
Community Speaker Programs
Live speaking engagements by
contracted speakers are held at AIDS
Service Organizations (ASOs) and
Community-Based Organizations (CBOs),
educating people living with HIV on basic
HIV information, as well as specific
product information.
Educational Office Chart and Tearpad
Wall chart depicting the most common
antiretroviral agents, which can be used as
an educational tool during office visits,
and an accompanying tearpad serves as
a post–office visit reminder of the ARV
regimen discussed. Both are delivered
by a sales representative or offered in
downloadable form on product websites.
Videos
• An HIV testing video stresses the
importance of getting tested for HIV,
and what to expect
• The Journey series of videos is designed
to help those newly diagnosed with HIV/
AIDS to consider starting treatment. Four
videos are available at youtube.com and
on The Virology Portal
www.janssentherapeutics.com
Janssen Therapeutics, Division of Janssen Products, LP
Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ 08560
© Janssen Therapeutics, Division of Janssen Products, LP 2014 01/14 008569-140115
The foundation for personal success
Additional resources
Digital Patient Product Information
Web-based interactive package
information allows people living with
HIV to listen to, watch, and read
patient information.
Therapy Initiation Kits
Delivered to you by your Janssen
Therapeutics representative, kits
contain information for people living
with HIV on taking medication,
maintaining a healthy lifestyle, and
accessing savings programs.
Programs to Help People Living With
HIV to Stay on Treatment
Ask your Janssen Therapeutics
representative about tools and medication
reminder programs that help remind
patients to take their HIV medication.
These include email programs, direct
communications from select pharmacies to
provide medication tips and helpful tools,
and a medication reminder app available for
the iPhone®, Android™, and Blackberry®.
Johnson & Johnson Patient Assistance
Foundation (JJPAF)
This independent, nonprofit organization
enrolls people without adequate financial
resources and prescription coverage into
the Patient Assistance Program (PAP). Go
to www.jjpaf.org, call 1-800-652-6227, or
fax 1-888-526-5168 for details.
Patient Savings Program (PSP)
Enables people living with HIV who
have commercial prescription coverage
but pay high co-pays or co-insurance to
apply for eligibility to receive Janssen
HIV medications for up to 1 year at
reduced cost. For information, visit
www.janssentherapeutics.com/accessto-medicines or call 1-800-961-7169.
JanssenTherapeuticsLine
A toll-free hotline answering
reimbursement questions, including
benefit verification, prior authorization
requirements, appeal process and
procedures, and alternate payment
sources. For specific reimbursement
queries, have personal information,
physician information, and financial
information available. Call 1-866-836-0114
or fax 1-866-836-0567, Monday-Friday,
9 AM-8 PM, ET.
HarborPath AIDS Drug Assistance
Program (ADAP) Waiting List Initiative
Johnson & Johnson is a partner in
expediting access to HIV medication for
people living with HIV on ADAP waiting
lists. ADAP coordinators confirm eligibility.
HarborPath then ships these medications
directly, and at no cost. Learn more at
www.harborpath.org/wait-list#adap.
All trademarks and registered trademarks are the
property of their respective owners.
www.janssentherapeutics.com
Janssen Therapeutics, Division of Janssen Products, LP
Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ 08560
© Janssen Therapeutics, Division of Janssen Products, LP 2014 01/14 008569-140115
In a continuously
evolving field
of treatment, you
need up-to-date
information at
your fingertips.
volutio
Professional
reinforcement
Janssen Therapeutics has
developed an assortment of
educational tools and resources
to support the care that you
and your colleagues provide to
people living with HIV.
Educational
opportunities
and office
resources
Providing you with
educational opportunities
Webcasts
Live Webcasts
Speaker Programs
Presentations by local and
national speakers
E-mail and Interactive Forums
Timely and relevant information
delivered right to your inbox
Healthcare Reform
News & Support
Webinars and support material
about healthcare reform and how
it impacts HIV care
Assisting you with
resources for your practice
Web-based Resource Portal
The service provider’s ultimate
online virology resource
Professional reinforcement
In a continuously evolving field of treatment, you need up-to-date
information at your fingertips. Janssen Therapeutics has developed
an assortment of educational tools and resources to support the care
that you and your colleagues provide to people living with HIV.
Providing you with
educational opportunities
Assisting you with resources
for your practice
Webcasts
Webcasts cover topics ranging from
general to specific, including product
information, challenges of managing
treatment-experienced patients,
neurocognitive and behavioral issues
in HIV, and case challenges.
Web-Based Resource Portal
The Virology Portal is an easy-to-use online
resource providing an array of tools and
educational materials for service providers,
including a customized brochure builder,
office staff training modules on background
HIV information, and a Continuing
Education (CE) credit tracker. Go to
www.virologyportal.com.
Speaker Programs
Physician-oriented presentations by local
or national speakers cover HIV topics, such
as aging with HIV, acute HIV infection,
and women and HIV. Ask your Janssen
Therapeutics representative about
programs near you.
E-mail Programs and Interactive Forums
Get HIV news and updates, conference and
event information, Janssen product news,
and more—delivered right to your inbox.
Healthcare Reform News
Support material including Webinars,
emails, and newsletters about the impact of
healthcare reform and the Affordable Care
Act on people living with HIV.
www.janssentherapeutics.com
Janssen Therapeutics, Division of Janssen Products, LP
Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ 08560
© Janssen Therapeutics, Division of Janssen Products, LP 2014 01/14 008569-140115
From product research to product
development, the Janssen
Pharmaceutical Companies of
Johnson & Johnson care about
finding ways to improve treatment
for people living with HIV and
other infectious diseases.
In addition to ARV therapy,
Janssen has also developed
therapies for other branches of
virology, such as hepatitis C and
tuberculosis. Janssen is also
partnering with other companies
to create treatment options like
fixed-dose combinations that may
help reduce a patient’s pill burden.
research &
development
Supporting
the future
Supporting the future of HIV
From product research to product development, the Janssen
Pharmaceutical Companies of Johnson & Johnson care about finding
ways to improve treatment for people living with HIV and other
infectious diseases.
In addition to ARV therapy, Janssen has also developed therapies
for other branches of virology, such as hepatitis C and tuberculosis.
Janssen is also partnering with other companies to create treatment
options like fixed-dose combinations that may help reduce a patient’s
pill burden.
Researching and developing
treatments
Fixed-Dose Combinations
Janssen has developed partnerships with
other companies to develop fixed-dose
combinations of antiretroviral medications.
Long-Acting Formulations
Janssen is undertaking research in the
development of longer acting formulations
of existing products for potential use in
prevention and/or maintenance therapy.
HIV Microbicide
Janssen has licensed an NNRTI to the
International Partnership for Microbicides,
which is currently under development for
potential use as a long-term, controlledrelease vaginal HIV microbicide.
HIV Vaccination
This active preclinical program aims
to develop an HIV vaccine with our sister
company, Crucell.
The Gender, Race, And Clinical
Experience (GRACE) Study
The largest HIV/AIDS study to date in
North American treatment-experienced
women evaluated the efficacy, safety, and
tolerability of ARV combination therapy
for this population.
Beyond HIV
Beyond ARV medications, Janssen has also
developed medications for the treatment
of hepatitis C and tuberculosis.
www.janssentherapeutics.com
Janssen Therapeutics, Division of Janssen Products, LP
Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ 08560
© Janssen Therapeutics, Division of Janssen Products, LP 2014 01/14 008569-140115
Community-based funding to help improve the
HIV treatment cascade
NHA
Supporting
the HIV community
at large
Because the HIV community spans the globe, Janssen
has broadened the reach of our care to ensure that we
are benefiting the HIV community on a larger scale.
Through national Request-for-Proposal (RFP) initiatives, Janssen Therapeutics
has provided more than $2.4 million since 2008 in support of community-based
HIV/AIDS programs that help improve linkage to care, retention in care,
and treatment education for underserved populations. Our company has
also provided multi-year support for AIDS United’s “Access 2 Care” initiative,
which aims to improve access to and retention in effective HIV health care
and support services for difficult-to-reach populations. In 2013, we addressed
another critical unmet need by supporting regional and national training on the
Affordable Care Act for HIV/AIDS medical and service providers. Learn more
at www.janssentherapeutics-grants.com.
Making a global impact
Janssen Global Access & Partnerships Program (GAPP)
The GAPP’s primary focus is to provide sustainable access to Janssen HIV
medicines in countries with high HIV burden and economic vulnerability. Direct
licensing agreements sustainably broaden the reach of Janssen’s branded
HIV medicines at reduced special effort access prices in Sub-Saharan Africa
(SSA) and least developed countries (LDCs). Based on expanding patient need,
additional licensing agreements enable the manufacture of generic versions
of two Janssen HIV medicines as well as fixed-dose combinations (FDCs). The
generic agreements cover as many as 112 countries, home to 88% of people living
with HIV in resource-limited countries. GAPP also supports global initiatives to
potentially simplify and standardize FDC regimens for first-, second-, and
third-line therapy. Learn more at www. janssenrnd.com/our-caring/global-access.
Johnson & Johnson Giving
In 2012, Johnson & Johnson improved the lives of people around the world with
nearly 600 programs in more than 50 countries—and more than $966 million
in funds and products. In fact, among corporate funders in the United States,
Johnson & Johnson is one of the top 10 largest contributors to HIV-related
causes here and around the world.
Models used in this brochure are for illustrative purposes only.
All trademarks and registered trademarks are the property of their respective owners.
www.janssentherapeutics.com
Janssen Therapeutics, Division of Janssen Products, LP
Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ 08560
© Janssen Therapeutics, Division of Janssen Products, LP 2014 01/14 008569-140115
We are st
of the Na
Strategy
we demo
commitm
commun
its 3 prim
È
Re
wh
Increasing access to
improving health
for people living
È
Reduci
health